相关实验视频
Updated: Apr 29, 2026

10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
20.7K
使用响应表面方法设计和优化双 Ca2+ 和 SO4 离子交联的素/pectin 微珠,用于结肠特异性输送
Wasim Akram1, Nitin Singh2, Kantrol Kumar Sahu3
1Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, India.
Journal of biomaterials science. Polymer edition
|January 15, 2025
概括
开发了双重交联的素-pectin微珠,用于性结肠炎的向治疗. 这些响应pH的珠子提供了增强的结肠药物递送和保留,显示出作为粘膜粘合剂载体的潜力.
科学领域:
- 材料科学 材料科学 材料科学
- 聚合物化学 聚合物化学
- 药品制造 药品制造 药品制造
背景情况:
- 性结肠炎需要有针对性的结肠药物输送.
- 为此目的,多糖类提供pH响应和可生物降解的特性.
研究的目的:
- 开发和优化双交叉链接的血清素 - pectin (DCLSPs) 微珠,用于结肠特异性梅沙胺的输送.
- 对性结肠炎的治疗和向效率进行评估.
主要方法:
- 通过具有Ca2+和SO42-交联离子的离子转化凝制剂.
- 使用响应表面方法 (盒式设计) 的优化.
- 对封装效率,加载,膨胀,形态和体外释放的评估.
主要成果:
- 球形DCLSPs微珠成功地准备了高封装效率 (65.1-95.5%) 和药物加载 (32.5-49.9%).
- 珠子表现出pH响应的胀和通过扩散和胀机制控制的药物释放.
- 优化的配方显示了增强的粘膜粘合和延长结肠中的保留.
结论:
- 双重交叉链接的素-pectin微珠是有希望的粘粘性载体,用于结肠特异性药物输送.
- 开发的系统提高了性结肠炎治疗的治疗效率.
- 素的结合提高了颗粒大小分布分析的准确性.
相关概念视频
Modified-Release Drug Delivery Systems: Site-Targeted
161
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
161
Site-Targeted Drug Delivery Systems: Polymeric Carriers
159
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
159

